Pharmacokinetics of solifenacin in pediatric populations with overactive bladder or neurogenic detrusor overactivity

The aim of this investigation was to characterize and compare the pharmacokinetics (PK) of the antimuscarinic drug solifenacin in pediatric patients with overactive bladder (OAB) or neurogenic detrusor overactivity (NDO) utilizing data from three phase III trials. LION was a placebo‐controlled, 12‐w...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Pharmacology research & perspectives 2020-12, Vol.8 (6), p.e00684-n/a
Hauptverfasser:	Tannenbaum, Stacey, den Adel, Martin, Krauwinkel, Walter, Meijer, John, Hollestein‐Havelaar, Adriana, Verheggen, Frank, Newgreen, Donald
Format:	Artikel
Sprache:	eng
Schlagworte:	Adolescent Adults Bioavailability Bladder Child Child, Preschool Dose-Response Relationship, Drug Double-Blind Method Drug dosages Female Humans Infant Male Muscarinic Antagonists - administration & dosage Muscarinic Antagonists - pharmacokinetics nephrology – urology Original Patients Pediatrics pediatrics – children Pharmacokinetics Pharmacology Plasma Single-Blind Method Solifenacin Succinate - administration & dosage Solifenacin Succinate - pharmacokinetics Teenagers Urinary Bladder, Overactive - diagnosis Urinary Bladder, Overactive - drug therapy Urinary Bladder, Overactive - metabolism Urinary incontinence Urological Agents - administration & dosage Urological Agents - pharmacokinetics
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	The aim of this investigation was to characterize and compare the pharmacokinetics (PK) of the antimuscarinic drug solifenacin in pediatric patients with overactive bladder (OAB) or neurogenic detrusor overactivity (NDO) utilizing data from three phase III trials. LION was a placebo‐controlled, 12‐week trial in children (5–
ISSN:	2052-1707 2052-1707
DOI:	10.1002/prp2.684